New translational strategy for personalised treatment of type 2 diabetes
Type 2 diabetes (T2D), or adult-onset diabetes, affects hundreds of millions of people worldwide and represents a health problem of enormous proportions. Current treatment strategies are unable to stop disease progression and prevent its devastating complications. Recent studies found that T2D patients can be divided into four clusters suggesting that anti-diabetic treatment should ideally target the underlying pathophysiology of individual patients. The overall goal of the EU-funded TRANSLATIONAL project is to test this approach by tailoring existing and new treatments to patients who are archetypes of the two most severe T2D clusters, those with poor insulin secretion and those with significant insulin resistance. The project aims to study new compounds for personalised treatment including sulforaphane as an early intervention for cases with severe insulin resistance.
Fields of science
Funding SchemeERC-COG - Consolidator Grant
405 30 Goeteborg
See on map